Coronavirus Resources:
BARDA’s Expanding
COVID-19 Medical Countermeasure Portfolio
BARDA has a proven track record of responding to pandemics and developing lifesaving medical countermeasures. We are rapidly executing new partnerships and building a robust COVID-19 MCM Portfolio because Americans deserve to have safe, effective medical products.
Follow Us
Be the first to get updated on the progress of BARDA Portfolio Partners. Sign-up for our email announcements:
This page is updated regularly, but may not include all awards
- All
- Vaccines
- Diagnostics
- Therapeutics
- Rapidly Deployable Capabilities
- Other
BARDA'S Impact of Diagnostic Investments
Rapidly deploying test kits to Americans
134.3M+
Diagnostic Test Kits Shipped by Partners
*as of July 30, 2021